H.C. Wainwright lowered the firm’s price target on Invivyd (IVVD) to $5 from $10 and keeps a Buy rating on the shares following the Q1 revenue shortfall. Invivyd’s platform continues to evolve beyond COVID-19, with early signs of operational stabilization and pipeline expansion emerging in Q2, the analyst tells investors in a research note. The firm believes the company is transitioning from a single-asset COVID-19 story to a broader antibody-based infectious disease platform. It believes Invivyd has “multiple potential catalysts for near-term value creation.”
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IVVD:
- Invivyd announces results from CANOPY Phase 3 trial
- Invivyd announces PEMGARDA has been added to NCCN Clinical Practice Guidelines
- Invivyd ‘commends’ FDA focus on uncertainty around COVID-19 vaccine boosters
- Invivyd Holds Annual Stockholders Meeting, Elects Directors
- Invivyd Reports Q1 2025 Financial Results and Outlook